Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABPI Proposes ‘World-First’ Investment Facility As Part Of New Pricing Deal

A ‘Medicines Equity Partnership’ Is Also On The Cards

Executive Summary

The Association of the British Pharmaceutical Industry says a new type of investment facility funded by the pharmaceutical industry could form part of a new pricing agreement for branded medicines, and would be a “genuine Brexit dividend.”

You may also be interested in...



Big Pharma Accused Of 'Ripping Off NHS'

A new report accuses big pharma of excessive pricing and costing the National Health Service billions of pounds. The Association of the British Pharmaceutical Industry has refuted the claims.

UK Government And Industry Still Far Apart In Talks on New Pricing Scheme

The UK pharmaceutical industry association, the ABPI, says it and the government are still far from reaching a deal on a new voluntary pricing agreement and has suggested that a transition to the statutory scheme could be on the cards if an acceptable deal cannot be secured.

ABPI Chooses Pfizer’s Susan Rienow As New President

Susan Rienow, UK country president of Pfizer, is to formally replace Pinder Sahota, UK manager of Novo Nordisk, as president of the UK pharmaceutical industry trade group, the ABPI.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel